Compare Stocks: IMA, DTIL, ELDN, and TRDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$7.27 +7.0%	$6.97	$3.53 ▼ $9.62	$200.07M	1.27	308,888 shs	101,959 shs
ELDN Eledon Pharmaceuticals	$2.68 +11.0%	$2.73	$1.35 ▼ $4.60	$209.98M	0.84	1.14 million shs	874,736 shs
IMA ImageneBio	$4.14 +3.0%	$4.76	$3.88 ▼ $9.10	$47.00M	0.74	119,967 shs	19,378 shs
TRDA Entrada Therapeutics	$4.79 +8.5%	$6.22	$4.11 ▼ $16.45	$186.66M	-0.24	331,727 shs	237,820 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	+5.93%	+3.51%	+9.16%	-1.45%	-5.43%
ELDN Eledon Pharmaceuticals	+9.05%	+6.64%	-9.06%	-27.19%	-37.08%
IMA ImageneBio	-0.74%	-2.66%	-14.83%	-27.83%	-51.86%
TRDA Entrada Therapeutics	-7.16%	-11.62%	-28.41%	-32.67%	-39.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$7.27 +7.0%	$6.97	$3.53 ▼ $9.62	$200.07M	1.27	308,888 shs	101,959 shs
ELDN Eledon Pharmaceuticals	$2.68 +11.0%	$2.73	$1.35 ▼ $4.60	$209.98M	0.84	1.14 million shs	874,736 shs
IMA ImageneBio	$4.14 +3.0%	$4.76	$3.88 ▼ $9.10	$47.00M	0.74	119,967 shs	19,378 shs
TRDA Entrada Therapeutics	$4.79 +8.5%	$6.22	$4.11 ▼ $16.45	$186.66M	-0.24	331,727 shs	237,820 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	+5.93%	+3.51%	+9.16%	-1.45%	-5.43%
ELDN Eledon Pharmaceuticals	+9.05%	+6.64%	-9.06%	-27.19%	-37.08%
IMA ImageneBio	-0.74%	-2.66%	-14.83%	-27.83%	-51.86%
TRDA Entrada Therapeutics	-7.16%	-11.62%	-28.41%	-32.67%	-39.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	343.91% Upside
ELDN Eledon Pharmaceuticals	2.33	Hold	$10.00	273.83% Upside
IMA ImageneBio	1.67	Reduce	$28.00	576.17% Upside
TRDA Entrada Therapeutics	2.43	Hold	$17.75	270.95% Upside

Current Analyst Ratings Breakdown

Latest IMA, DTIL, ELDN, and TRDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	TRDA Entrada Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral
10/19/2026	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral
10/16/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/2/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/25/2026	IMA ImageneBio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/21/2026	ELDN Eledon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/16/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	IMA ImageneBio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$28.00
8/21/2026	IMA ImageneBio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$28.00
8/13/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTIL Precision BioSciences	$34.26M	5.85	N/A	N/A	$4.03 per share	1.80
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.35 per share	N/A
IMA ImageneBio	$800K	58.76	N/A	N/A	$11.91 per share	0.35
TRDA Entrada Therapeutics	$4.69M	39.76	N/A	N/A	$8.01 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTIL Precision BioSciences	-$45.72M	-$2.80	N/A	N/A	N/A	-96.73%	-72.52%	-32.25%	11/2/2026 (Estimated)
ELDN Eledon Pharmaceuticals	-$45.62M	-$0.91	N/A	N/A	N/A	N/A	-149.63%	-50.84%	11/13/2026 (Estimated)
IMA ImageneBio	-$45.35M	-$4.58	N/A	N/A	N/A	N/A	-38.99%	-34.84%	N/A
TRDA Entrada Therapeutics	-$143.75M	-$3.96	N/A	N/A	N/A	-3,537.73%	-57.61%	-46.54%	11/5/2026 (Estimated)

Latest IMA, DTIL, ELDN, and TRDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	ELDN Eledon Pharmaceuticals	-$0.20	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	TRDA Entrada Therapeutics	-$0.98	N/A	N/A	N/A	$2.13 million	N/A
11/2/2026	Q3 2026	DTIL Precision BioSciences	-$0.85	N/A	N/A	N/A	$1.38 million	N/A
8/13/2026	Q2 2026	ELDN Eledon Pharmaceuticals	-$0.1580	-$0.27	-$0.1120	-$0.27	N/A	N/A
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.8040	-$1.26	-$0.4560	-$1.26	$0.74 million	N/A
8/5/2026	Q2 2026	IMA ImageneBio	-$0.90	-$0.63	+$0.27	-$0.63	N/A	N/A
8/5/2026	Q2 2026	TRDA Entrada Therapeutics	-$0.9738	-$1.01	-$0.0363	-$1.01	$2.32 million	$0.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMA ImageneBio	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTIL Precision BioSciences	0.50	12.82	12.82
ELDN Eledon Pharmaceuticals	N/A	7.90	7.90
IMA ImageneBio	N/A	21.47	21.47
TRDA Entrada Therapeutics	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTIL Precision BioSciences	37.99%
ELDN Eledon Pharmaceuticals	56.77%
IMA ImageneBio	75.00%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
DTIL Precision BioSciences	2.70%
ELDN Eledon Pharmaceuticals	9.60%
IMA ImageneBio	2.22%
TRDA Entrada Therapeutics	9.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTIL Precision BioSciences	67	27.60 million	26.86 million	Optionable
ELDN Eledon Pharmaceuticals	33	81.26 million	73.46 million	Optionable
IMA ImageneBio	18	11.35 million	11.10 million	Not Optionable
TRDA Entrada Therapeutics	152	38.94 million	35.24 million	Optionable

IMA, DTIL, ELDN, and TRDA Headlines

Recent News About These Companies

Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Raised to Hold at Wall Street Zen

October 24, 2026 | marketbeat.com

Entrada Therapeutics, Inc. Announces Appointment of Linea Aspesi as Chief People Officer

October 22, 2026 | marketscreener.comM

Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer

October 21, 2026 | globenewswire.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Average Price Target of $17.75

October 18, 2026 | marketbeat.com

Entrada Therapeutics Advances Duchenne Study To Highest Planned Dose Level

October 14, 2026 | rttnews.com

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

October 14, 2026 | markets.businessinsider.com

Entrada Therapeutics clears DMC review, advances DMD study to top dose

October 14, 2026 | streetinsider.com

Entrada Therapeutics Shares Drop 15% After Phase 1/2 Trial Results

October 14, 2026 | kucoin.comK

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

October 14, 2026 | globenewswire.com

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

October 14, 2026 | globenewswire.com

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

October 10, 2026 | seekingalpha.com

Entrada Therapeutics, Inc.: Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

September 10, 2026 | finanznachrichten.de

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

September 10, 2026 | globenewswire.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 28,837 Shares of Stock

September 10, 2026 | insidertrades.com

Analysts Conflicted on These Healthcare Names: Definitive Healthcare Corp (DH) and Entrada Therapeutics Inc (TRDA)

September 5, 2026 | theglobeandmail.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in Stock

September 4, 2026 | insidertrades.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026 | globenewswire.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

September 1, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $102,857.14 in Stock

August 27, 2026 | insidertrades.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares of Stock

August 11, 2026 | insidertrades.com

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

August 5, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMA, DTIL, ELDN, and TRDA Company Descriptions

Precision BioSciences NASDAQ:DTIL

$7.26 +0.48 (+7.00%)

As of 02:52 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Eledon Pharmaceuticals NASDAQ:ELDN

$2.68 +0.27 (+11.00%)

As of 02:53 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

ImageneBio NASDAQ:IMA

$4.14 +0.12 (+3.01%)

As of 02:36 PM Eastern

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Entrada Therapeutics NASDAQ:TRDA

$4.78 +0.38 (+8.50%)

As of 02:52 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMA, DTIL, ELDN, and TRDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMA, DTIL, ELDN, and TRDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMA, DTIL, ELDN, and TRDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMA, DTIL, ELDN, and TRDA Company Descriptions

Precision BioSciences NASDAQ:DTIL

Eledon Pharmaceuticals NASDAQ:ELDN

ImageneBio NASDAQ:IMA

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMA, DTIL, ELDN, and TRDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMA, DTIL, ELDN, and TRDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMA, DTIL, ELDN, and TRDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMA, DTIL, ELDN, and TRDA Company Descriptions

Precision BioSciences NASDAQ:DTIL

Eledon Pharmaceuticals NASDAQ:ELDN

ImageneBio NASDAQ:IMA

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools